RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

Cited by (687)

Items 501–600 of 687

1. Premature delivery in the domestic sow in response to in utero delivery of AAV9 to fetal piglets
   Kelly A. Rich, Christopher G. Wier, Jessica R. Russo, Lingling Kong, Patrick L. Heilman, Anthony Reynolds, Amy Knapp, Megan G. Pino, Elizabeth Keckley, Lori Mattox et al. · 2021 · Gene Therapy
2. Brain-wide TVA compensation allows rabies virus to retrograde target cell-type-specific projection neurons
   Zengpeng Han, Nengsong Luo, Jiaxin Kou, Lei Li, Zihong Xu, Siyuan Wei, Yang Wu, Jie Wang, Chaohui Ye, Kunzhang Lin et al. · 2022 · Molecular Brain
3. Spinal Muscular Atrophy: Classification, Diagnosis, Background, Molecular Mechanism and Development of Therapeutics
   Faraz A Tariq, Martin Holčı́k, Alex MacKenzie · 2013 · InTech eBooks
4. In-depth comparison of Anc80L65 and AAV9 retinal targeting and characterization of cross-reactivity to multiple AAV serotypes in humans
   Maura K. Schwartz, Shibi B. Likhite, Tatyana A. Vetter, Megan Baird, Vicki L. McGovern, Julieth A. Sierra-Delgado, Tom Mendel, Arthur H.M. Burghes, Kathrin Meyer · 2023 · Molecular Therapy — Methods & Clinical Development
5. U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing
   Namjeong Choi, Yongchao Liu, Jagyeong Oh, Jiyeon Ha, Xuexiu Zheng, Haihong Shen · 2020 · Cells
6. Initial gene vector dosing for studying symptomatology of amyotrophic lateral sclerosis in non‐human primates
   Kasey L. Jackson, Robert D. Dayton, Jeanne M. Fisher‐Perkins, Peter J. Didier, Kate C. Baker, Maria B. Weimer, Amparo Gutierrez, Cooper D. Cain, James Michael Mathis, Michael A. Gitcho et al. · 2015 · Journal of Medical Primatology
7. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy
   E. Dachs, Lídia Piedrafita, Marta Hereu, Josep Enric Esquerda, Jordi Calderó · 2013 · Neuroscience
8. Current Advances in Vehicles for Brain Gene Delivery
   Xiang Zhang, Lili Zhao, Jinhui Wu, Hong Dong, Feng Xu, Guangming Gong, Yiqiao Hu · 2012 · Current Gene Therapy
9. Optimizing Mouse Models of Neurodegenerative Disorders: Are Therapeutics In Sight?
   Cathleen M. Lutz, Melissa A. Osborne · 2013 · Future Neurology
10. Nonmammalian Animal Models of Spinal Muscular Atrophy
    Patrick O’Hern, Eric L. Garcia, L.T. Hao, Anne C. Hart, A. Gregory Matera, Christine E. Beattie · 2016 · Elsevier eBooks
11. Blood Flow to the Spleen is Altered in a Mouse Model of Spinal Muscular Atrophy
    Marc‐Olivier Deguise, Ariane Beauvais, Bernard Laurent Schneider, Rashmi Kothary · 2020 · Journal of Neuromuscular Diseases
12. Advances and challenges in developing a therapy for spinal muscular atrophy
    Ryan S. Anderton, Frank Louis Mastaglia · 2015 · Expert Review of Neurotherapeutics
13. Genetic Diseases, Immunology, Viruses, and Gene Therapy
    James M. Wilson · 2014 · Human Gene Therapy
14. Update on gene and stem cell therapy approaches for spinal muscular atrophy
    Eleanor M. Donnelly, Nicholas M. Boulis · 2012 · Expert Opinion on Biological Therapy
15. Viral Vectors for Studying Brain Mechanisms that Control Energy Homeostasis
    Mancini, Giacomo, Horvath, Tamas L. · 2018 · Cell Metabolism
16. Call in the backup
    Elie Dolgin · 2012 · Nature Medicine
17. Gestational Age-Dependent Increase of Survival Motor Neuron Protein in Umbilical Cord-Derived Mesenchymal Stem Cells
    Sota Iwatani, Nur Imma Fatimah Harahap, Dian Kesumapramudya Nurputra, Shinya Tairaku, Akemi Shono, Daisuke Kurokawa, Keiji Yamana, Khin Kyae Mon Thwin, Makiko Yoshida, Masami Mizobuchi et al. · 2017 · Frontiers in Pediatrics
18. Infectivity Assessment of Recombinant Adeno-Associated Virus and Wild-Type Adeno-Associated Virus Exposed to Various Diluents and Environmental Conditions
    Taro Tomono, Yukihiko Hirai, Hideto Chono, Junichi Mineno, Akiko Ishii, Masafumi Onodera, Akira Tamaoka, Takashi Okada · 2019 · Human Gene Therapy Methods
19. Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
    Manisha Singh, Surinder Pal Singh, Deepshikha Yadav, Mugdha Agarwal, Shriya Agarwal, Vinayak Agarwal, Geeta Swargiary, Sahil Srivastava, Sakshi Tyagi, Ramneek Kaur et al. · 2020 · Current Gene Therapy
20. Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives
    Ana Fajardo‐Serrano, Alberto J. Rico, Elvira Roda, Adriana Honrubia, Sandra Arrieta, Goiaz Ariznabarreta, Julia Chocarro, Elena Lorenzo-Ramos, Álvaro Pejenaute, Alfonso Vázquez et al. · 2022 · Biomedicines
21. SMN Is Physiologically Downregulated at Wild-Type Motor Nerve Terminals but Aggregates Together with Neurofilaments in SMA Mouse Models
    Julio Franco-Espín, Alaó Gatius, Jose Angel Armengol, Saravanan Arumugam, Mehri Moradi, Michael Sendtner, Jordi Calderó, Lucı́a Tabares · 2022 · Biomolecules
22. Atrofia muscular espinal: revisión de nuestra casuística en los últimos 25 años
    Aurora Madrid Rodríguez, Pablo Martínez, José Miguel Ramos‐Fernández, AL Urda Cardona, J. Martínez Antón · 2014 · Anales de Pediatría
23. Mammalian Models of Spinal Muscular Atrophy
    Arthur H.M. Burghes, Christine J. DiDonato, Vicki L. McGovern, William David Arnold · 2016 · Elsevier eBooks
24. Genetics of Spinal Muscular Atrophy
    Arthur H.M. Burghes, Vicki L. McGovern · 2017 · Elsevier eBooks
25. Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB/NJ-Ighmpb2
    Monir Shababi, Caley E. Smith, Sara M. Ricardez Hernandez, Jose Marquez, Zayd Al Rawi, Eric Villalón, K. David Farris, Mona O. Garro-Kacher, Christian L. Lorson · 2021 · Molecular Therapy — Methods & Clinical Development
26. Assuring long-term safety of highly effective gene-modulating therapeutics for rare diseases
    Thomas O. Crawford, Charlotte J. Sumner · 2021 · Journal of Clinical Investigation
27. The Proteome Signatures of Fibroblasts from Patients with Severe, Intermediate and Mild Spinal Muscular Atrophy Show Limited Overlap
    Sharon J. Brown, Rachel A. Kline, Silvia A. Synowsky, Sally L. Shirran, Ian Holt, Kelly A. Sillence, Peter Claus, Brunhilde Wirth, Thomas M. Wishart, Heidi R. Fuller · 2022 · Cells
28. Treatment strategies for spinal muscular atrophy
    Heidi R. Fuller, Marija Barišić, Đurđica Šešo-Šimić, Tea Špeljko, Glenn Morris, Goran Šimić · 2010 · Translational Neuroscience
29. Development and Testing of Biomarkers in Spinal Muscular Atrophy
    William David Arnold, Louise R. Simard, Seward B. Rutkove, Stephen J. Kolb · 2016 · Elsevier eBooks
30. Raise the Roof: Boosting the Efficacy of a Spinal Muscular Atrophy Therapy
    Nicholas J. Kramer, Aaron D. Gitler · 2017 · Neuron
31. In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson’s disease
    Lucie Chansel‐Debordeaux, Mathieu Bourdenx, Sandra Doveró, Virginie Grouthier, Nathalie Dutheil, Agnès Espana, Laurent Groc, Clément Jimenez, Erwan Bézard, Benjamin Dehay · 2017 · Gene Therapy
32. Local transgene expression and whole‐body transgenesis to model brain diseases in nonhuman primate
    Lucie Chansel‐Debordeaux, Erwan Bézard · 2019 · Animal Models and Experimental Medicine
33. Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies
    Carsten Werner Lederer, Lola Koniali, Tina Buerki‐Thurnherr, Panayiota L. Papasavva, Stefania La Grutta, Amelia Licari, František Štaud, Donato Bonifazi, Marina Kleanthous · 2022 · Pharmaceutics
34. Therapeutics in paediatric genetic diseases: current and future landscape
    Ai Ling Koh, Saumya Shekhar Jamuar · 2023 · Singapore Medical Journal
35. La atrofia muscular espinal en el nuevo escenario terapéutico
    Eduardo Fidel Tizzano · 2018 · Revista Médica Clínica Las Condes
36. Supraphysiological expression of survival motor neuron protein from an adenovirus vector does not adversely affect cell function
    Benoit Goulet, Emily R. McFall, Carmen M. Wong, Rashmi Kothary, Robin J. Parks · 2013 · Biochemistry and Cell Biology
37. AAV9‐mediated AIRE gene delivery clears circulating antibodies and tissue T‐cell infiltration in a mouse model of autoimmune polyglandular syndrome type‐1
    Sarah Abdullah Almaghrabi, Mimoun Azzouz, Rachid Tazi‐Ahnini · 2020 · Clinical & Translational Immunology
38. Motor defects in a Drosophila model for spinal muscular atrophy result from SMN depletion during early neurogenesis
    Stuart J. Grice, Ji‐Long Liu · 2022 · PLoS Genetics
39. IgG-cleavage protein allows therapeutic AAV gene delivery in passively immunized MPS IIIA mice
    Tierra A. Bobo, Preston N. Samowitz, Michael I. Robinson, Laura Montes, Lawrence J. Forsberg, Richard Feng, Nathan I. Nicely, Haiyan Fu · 2022 · Gene Therapy
40. Perinatal Gene Delivery to the CNS
    Ahad A. Rahim, Suzanne M. K. Buckley, Jerry Kok Yen Chan, Donald Peebles, Simon N. Waddington · 2011 · Therapeutic Delivery
41. AAV Engineering Identifies a Species Barrier That Highlights a Portal to the Brain
    Luk H. Vandenberghe · 2019 · Molecular Therapy
42. Spinal Muscular Atrophy
    Michelle Anne Farrar, Matthew C. Kiernan · 2011 · Encyclopedia of Life Sciences
43. Spinale Muskelatrophie
    Katharina Vill, Astrid Blaschek, Ulrike Schara, Heike Kölbel, Katharina Hohenfellner, Erik Harms, Bernd Olgemöller, Maggie Christine Walter, Wolfgang Müller‐Felber · 2017 · Der Nervenarzt
44. Strategy for Treating Motor Neuron Diseases Using a Fusion Protein of Botulinum Toxin Binding Domain and Streptavidin for Viral Vector Access: Work in Progress
    Daniel B. Drachman, Robert N. Adams, Uma Balasubramanian, Lu Yang · 2010 · Toxins
45. Effects of Astroglia on Motor Neurons in Spinal Muscular Atrophy
    Bert M. Verheijen · 2017 · Journal of Neuroscience
46. A crisis in US drug pricing: Consequences for patients with neuromuscular diseases, physicians, and society, part 2
    Ted M. Burns, Jason L. Crowell, A Gordon Smith · 2020 · Muscle & Nerve
47. Therapeutic potential of orphan drugs for the rare skeletal muscle diseases
    Kristy Swiderski, Gordon Stuart Lynch · 2015 · Expert Opinion on Orphan Drugs
48. Gene Therapy for Canavan's Disease Takes a Step Forward
    Seemin Seher Ahmed, Guangping Gao · 2013 · Molecular Therapy
49. Spinal muscular atrophy at the crossroads of basic science and therapy
    James N. Sleigh, Stuart J. Grice, Kay Elizabeth Davies, Kevin Talbot · 2012 · Neuromuscular Disorders
50. The influence of storage parameters on measurement of survival motor neuron (SMN) protein levels: Implications for pre-clinical studies and clinical trials for spinal muscular atrophy
    Gillian Hunter, Sarah Louise Roche, Eilidh Somers, Heidi R. Fuller, Thomas Henry Gillingwater · 2014 · Neuromuscular Disorders
51. Gene Therapy Products Reached to Market by 2021
    Sümbül Yıldırım, Fatih Kocabaş · 2021 · Gene Editing
52. Of SMN in mice and men: a therapeutic opportunity
    Kathryn J. Swoboda · 2011 · Journal of Clinical Investigation
53. Human Growth Hormone Increases SMN Expression and Survival in Severe Spinal Muscular Atrophy Mouse Model
    Duncan MacKenzie, Fahad Shamim, Kevin Mongeon, Ankur Trivedi, Alex MacKenzie, Faraz Farooq · 2014 · Journal of Neuromuscular Diseases
54. Spinal Muscular Atrophy
    Joseph R. Wooley, Melissa E. Crowder, Noah J. Pyles, Charlotte J. Sumner · 2017 · Neurodegeneration
55. Mitigating aberrant Cdk5 activation alleviates mitochondrial defects and motor neuron disease symptoms in spinal muscular atrophy
    Nimrod Miller, Zhaofa Xu, Katharina A. Quinlan, Amy Ji, Jered V. McGivern, Zhihua Feng, Han Shi, Chien‐Ping Ko, Li‐Huei Tsai, Charles J. Heckman et al. · 2023 · Proceedings of the National Academy of Sciences
56. Investigation of a recombinant SMN protein delivery system to treat spinal muscular atrophy
    Ryan S. Anderton, Bruno P. Meloni, Frank Louis Mastaglia, Sherif Boulos · 2014 · Translational Neuroscience
57. Treatment of Adult Spinal Muscular Atrophy: Overview and Recent Developments
    Svenja Brakemeier, Benjamin Stolte, Christoph Kleinschnitz, Tim Hagenacker · 2022 · Current Pharmaceutical Design
58. Enhanced expression of the human Survival motor neuron 1 gene from a codon-optimised cDNA transgene in vitro and in vivo
    Neda Ali Mohammadi Nafchi, Ellie M. Chilcott, Sharon J. Brown, Heidi R. Fuller, Mélissa Bowerman, Rafael J. Yáñez‐Muñoz · 2023 · Gene Therapy
59. AAV gene replacement therapy for treating MPS IIIC: Facilitating bystander effects via EV‐mRNA cargo
    Tierra A. Bobo, Michael J. Robinson, Christopher Tofade, Marina Sokolsky‐Papkov, Peter Nichols, Stephen Vorobiov, Haiyan Fu · 2024 · Journal of Extracellular Vesicles
60. Prediction of death in the SMNΔ7 mouse model of spinal muscular atrophy: Insight into disease stage and progression
    Bassem F. El‐Khodor, Kim Cirillo, Jose A. Beltran, Richard A. Mushlin, Margaret L. Winberg, Rachel Charney, Olga Chomicova, Tara Marino, Sylvie Ramboz · 2012 · Journal of Neuroscience Methods
61. Spinal Muscular Atrophy Therapeutics Development
    Sara Sunshine, Jill Jarecki, Alex MacKenzie, K.S. Chen · 2016 · Elsevier eBooks
62. Contributions of Different Cell Types to Spinal Muscular Atrophy Pathogenesis
    Marc‐Olivier Deguise, Teresa N. Patitucci, Allison D. Ebert, Christian L. Lorson, Rashmi Kothary · 2016 · Elsevier eBooks
63. 25 years of the SMN genes: the Copernican revolution of spinal muscular atrophy.
    Francesco Danilo Tiziano, Eduardo Fidel Tizzano · 2020 · PubMed Central
64. Strategy for the Molecular Testing of Spinal Muscular Atrophy
    Thomas W. Prior · 2016 · Elsevier eBooks
65. In vitro gene manipulation of spinal muscular atrophy fibroblast cell line using gene-targeting fragment for restoration of SMN protein expression
    Afrooz Rashnonejad, Cumhur Gündüz, Sunde Yılmaz Süslüer, Hüseyin Önay, Burak Durmaz, Mojgan Bandehpour, Ferda Özkınay · 2015 · Gene Therapy
66. A meditation on accelerating the development of small molecule medicines targeting RNA
    Xueyi Yang, Jessica L. Childs‐Disney, Matthew David Disney · 2022 · Expert Opinion on Drug Discovery
67. Gene replacement therapy to restore polyamine metabolism in a Snyder-Robinson syndrome mouse model
    Oluwaseun Akinyele, Krystal Tran, Marie A. Johnson, Dwi U. Kemaladewi · 2025 · Methods in enzymology on CD-ROM/Methods in enzymology
68. The expression of SMN1, MART3, GLE1 and FUS genes in spinal muscular atrophy
    Aziza Alrafiah, Maimonah S. Alghanmi, Sufana Almashhadi, Aqeel Aqeel, Adel Awaji · 2018 · Folia Histochemica et Cytobiologica
69. IL-1ra and CCL5, but not IL-10, are promising targets for treating SMA astrocyte-driven pathology
    Reilly L. Allison, Cecelia C Mangione, Mya Suneja, Jessica E. Gawrys, Brendan M. Melvin, Natalya Belous, Megan LaCroix, Matthew M. Harmelink, Barrington G. Burnett, Allison D. Ebert · 2024 · Molecular Therapy
70. Developments in the discovery of drugs for spinal muscular atrophy: successful beginnings and future prospects
    Rebecca M. Pruss · 2011 · Expert Opinion on Drug Discovery
71. How far away is spinal muscular atrophy gene therapy?
    Thomas Henry Gillingwater, Lyndsay M. Murray · 2015 · Expert Review of Neurotherapeutics
72. Challenges of Gene Therapy for Neurodegenerative Disorders
    Md. Sahab Uddin, Zeeshan Ahmad Khan, Dewan Md. Sumsuzzman, Asma Perveen, Ghulam Md Ashraf · 2020 · Current Gene Therapy
73. SMN haploinsufficiency promotes ischemia/ reperfusion‐induced AKI‐to‐CKD transition by endoplasmic reticulum stress activation
    Xiaoqian Qian, Jingyang Li, S Bian, Dongdong Zhu, Qin Guo, Fan Bian, Gengru Jiang · 2023 · The FASEB Journal
74. Spinal muscular atrophy - onasemnogene abeparvovec and other therapeutic options
    A. Majchrzak-Celińska, A. Warych, Mikołaj Szoszkiewicz · 2020 · Farmacja polska
75. Infantile spinal atrophy: Our experience in the last 25 years
    Aurora Madrid Rodríguez, Pablo Martínez, J.M. Ramos Fernández, AL Urda Cardona, J. Martínez Antón · 2015 · Anales de Pediatría (English Edition)
76. Neonatal systemic delivery of scAAV9 in rodents and large animals results in gene transfer to RPE cells in the retina
    Béatrice Joussemet, Brahim Belbellaa, Alexandra Mendes-Madeira, Thomas Bucher, Delphine Briot, Laurence Dubreil, Marie-Anne Colle, Yan Chérel, Philippe Moullier, Fabienne Rolling · 2011 · Experimental Eye Research
77. Antisense Oligonucleotides Shed New Light on the Pathogenesis and Treatment of Spinal Muscular Atrophy
    Jiing‐Kuan Yee, Ren-Jang Lin · 2012 · Molecular Therapy
78. Terapias avanzadas en enfermedades raras: la atrofia muscular espinal como ejemplo
    Eduardo Fidel Tizzano · 2018 · Medicina Clínica
79. Transplantation of Gene-Corrected Motor Neurons as a Therapeutic Strategy for Spinal Muscular Atrophy
    Kathrin Meyer, Carlos J. Miranda, Brian K. Kaspar · 2013 · Molecular Therapy
80. Models of hyperkinetic disorders in primates
    Erwan Bézard · 2019 · Journal of Neuroscience Methods
81. Gene Therapy in the Nervous System: Failures and Successes
    Jayanth S. Chandran, Joseph M. Scarrott, Pamela J. Shaw, Mimoun Azzouz · 2017 · Advances in experimental medicine and biology
82. Crossing the Blood-Brain Barrier with AAVs: What’s After SMA?
    Yujia A. Chan, Benjamin E. Deverman · 2022 · AAPS advances in the pharmaceutical sciences series
83. Advances in Spinal Muscular Atrophy Research
    Judith Melki · 2016 · Elsevier eBooks
84. A mouse model for spinal muscular atrophy provides insights into non-alcoholic fatty liver disease pathogenesis
    Marc‐Olivier Deguise, Chantal A. Pileggi, Ariane Beauvais, Alexandra Tierney, Lucia Chehadé, Yves De Repentigny, Jean Michaud, Maica Llavero Hurtado, Douglas J. Lamont, Abdelmadjid Atrih et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
85. An isogenic human iPSC model unravels neurodevelopmental abnormalities in SMA
    Tobias Graß, Ines Rosignol, Joshua D. Thomas, Felix Buchner, Zeynep Dokuzluoglu, Anna Dalinskaya, Jutta Becker, Brunhilde Wirth, Natalia Rodríguez‐Muela · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
86. AAV9-Mediated Intrastriatal Delivery of GNAO1 Reduces Hyperlocomotion in Gnao1 Heterozygous R209H Mutant Mice
    Alex J. Roy, Jeffrey R. Leipprandt, Joseph R. Patterson, Anna C. Stoll, Christopher J. Kemp, Zaipo-Tcheisian D. Oula, Tyler Mola, Ana Rita Batista, Caryl E. Sortwell, Miguel Sena‐Esteves et al. · 2024 · Journal of Pharmacology and Experimental Therapeutics
87. Exploration of a DDX3X Gene Supplementation Therapy Including Expanded Characterization and Novel Findings of Sleep Disturbances in Ddx3x Haploinsufficient Mice
    Andrea Boitnott, Anjala Jiji, Erik J. Plautz, Yuhui Hu, Xin Chen, Steven James Gray · 2025 · Biological Psychiatry Global Open Science
88. Drug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO‐10‐27
    Cynthia Bézier, Steve Cottin, Parvin Nazari Hashemi, Mirella El Khoury, Zoé Clerc, Christine Balducci, Delphine Sapaly, Laure Weill, René Lafont, Stanislas Veillet et al. · 2025 · Journal of Cachexia Sarcopenia and Muscle
89. AAV9-mediated NGLY1 gene replacement suppresses non-epileptic convulsions in Ngly1 rats
    Makoto Asahina, Reiko Fujinawa, Hiroto Hirayama, Hiroshi Yukitake, Tadashi Suzuki · 2025 · Biochemical and Biophysical Research Communications
90. Short-duration splice promoting compound enables a tunable mouse model of spinal muscular atrophy
    Anne Rietz, Kevin J. Hodgetts, Hrvoje Lusic, Kevin M. Quist, Erkan Y. Osman, Christian L. Lorson, Elliot J. Androphy · 2020 · Life Science Alliance
91. Temporal Requirements for the Survival Motor Neuron Protein
    Umrao R. Monani, Melissa A. Osborne, Cathleen M. Lutz · 2016 · Elsevier eBooks
92. Spinal muscular atrophy
    Bakri Elsheikh, Stephen J. Kolb, John T. Kissel · 2020 · Elsevier eBooks
93. Current and emerging treatment options for spinal muscular atrophy
    Faraz Farooq, Alex MacKenzie · 2015 · Degenerative Neurological and Neuromuscular Disease
94. Neuromuscular diseases: milestones in development of treatments
    Kate Bushby · 2010 · The Lancet Neurology
95. Generation of a tamoxifen inducible SMN mouse for temporal SMN replacement
    Thomas W. Bebee, Jordan T. Gladman, Dawn S. Chandler · 2011 · genesis
96. Treatmemt Options in Motor Neuron Disease: Amyotrophic Lateral Schlerosis and Spinal Muscular Atrophy
    James JM Loan, Stuart D. Connolly, David Z. Haunschmidt, Stephen B. Bell, Sophie A. Clarke, Joanne Kelly, Ailsa J. Oswald, Valerie Rae · 2012 · Biochemistry and Molecular Biology Education
97. Perinatal Gene Therapy
    Panicos Shangaris, Anna Louise David · 2016 · Stem cell biology and regenerative medicine
98. Viral Vectors in Primate Research: Examples from Parkinson’s Disease Research
    Grégory Porras, Benjamin Dehay, Erwan Bézard · 2013 · Neuromethods
99. Systemic Gene Delivery by Single-Dose Intracardiac Administration of scAAV2/9 and scAAV2/rh10 Variants in Newborn Rats
    Lucie Chansel‐Debordeaux, Mathieu Bourdenx, Nathalie Dutheil, Sandra Doveró, Marie‐Hélène Canron, Clément Jimenez, Erwan Bézard, Benjamin Dehay · 2018 · Human Gene Therapy Methods
100. Development and Optimization of the Manufacturing Process for RNA-Splicing Modifier Risdiplam RG7916
     Christian Moessner, Fabienne Hoffmann-Emery, Jean‐Michel Adam, Serena Fantasia, Dan Fishlock, Roland Meier, Georg Wuitschik, Hasane Ratni · 2022 · ACS symposium series